Full Press Release Details
Bio Inc. to Discuss Potential New Alzheimer's Disease Treatments in CTAD Pre-Conference Webinar
Bio's CEO, Dr. R.J. Tesi, will moderate a panel of experts from neuroscience research, clinical trials, and Alzheimer's
JOLLA, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company developing
treatments that harness the patient's innate immune system to fight disease, announced today its will host a live webinar
on Tuesday, Dec. 3, 2019, from 1:00 p.m. to 2:00 p.m. (EST) titled, "Bench to Bedside: A Pre-CTAD Webinar Highlighting
An Alternative Approach For Alzheimer's Disease." Attendees can register for the webinar by visiting https://russopartners.webex.com/russopartners/onstage/g.php?MTID=ea7cacd067c33e65bad04c76504eb28d2
host and moderator, INmune Bio's Chief Executive Officer, R.J. Tesi, M.D., will be joined by the following experts in Alzheimer's
the webinar, the panelists will discuss alternative approaches and therapeutics and methodological issues important to the development
of the next generation of Alzheimer's disease treatments. Following the panelists' presentations, webinar attendees
disease, one of the most devastating and frustrating diseases of our time, is a complex medical problem that will require more
than one therapeutic solution. Solving this problem will require hard work and persistence," said R.J. Tesi, M.D., Chief
Executive Officer of INmune Bio. "This group, of talented and experienced experts, on the eve of a highly anticipated
CTAD conference, will provide insight on how newer therapies for Alzheimer's disease might make a difference at the bedside
videotaped comments from Dr. Tesi and Dr. Tansey Alzheimer's disease research please follow this link: https://www.youtube.com/watch?v=XrLVjbaTolQ
Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments
that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform
utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic
target of many diseases. DN-TNF is currently being developed for cancer (INB03), Alzheimer's (XPro595), and NASH (NeuLiv).
The Innate Immune Priming Platform includes INKmune aimed at priming the patient's NK cells to eliminate minimal residual
disease in patients with cancer. INmune Bio's product platforms utilize a precision medicine approach for the treatment
of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.
Mal G. Tansey, Ph.D.
Tansey is the Norman Fixel Professor of Neuroscience and Neurology and Director of the Center for Translational Research in Neurodegenerative
Disease at the University of Florida College of Medicine. Dr. Tansey currently serves as a paid consultant for INmune Bio in support
of the company's Alzheimer's disease program. Dr. Tansey is an expert in the field of neuroinflammatory and immune
system responses in modulating the gene-environment interactions that determine risk for development and progression of neurodegenerative
and neuropsychiatric disease.
Forward-Looking Statements
statements contained in this press release that do not describe historical facts may constitute forward-looking statements as
that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein
are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain
events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks
and uncertainties. INB03 and XPro1595 are still in clinical trials and have not been approved and there cannot be any assurance
that they will be approved or that any specific results will be achieved. The factors that could cause actual future results to
differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's
ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue
its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's
business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other
factors are identified and described in more detail in the Company's filings with the Securities and Exchange Commission,
including the Company's Annual Report on Form 10-K for the year ended December 31, 2018, the Company's Quarterly Reports
on Form 10-Q and the Company's Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking
statements in order to reflect any event or circumstance that may arise after the date of this release.